#United States #Texas #Cellipont Bioservices #Xiogenix #Cell Therapy

Overview

In the fast-evolving field of cell therapy, scalability remains one of the main obstacles confronting manufacturers aiming to meet heightened clinical demands and commercial viability. Recently, Cellipont Bioservices, a prominent Contract Development and Manufacturing Organization (CDMO), in collaboration with Xiogenix, published a groundbreaking white paper titled "Scaling Cell and Gene Therapy Manufacturing with Automated Formulation and Fill-Finish." This document delves into the findings from their comprehensive evaluation of Xiogenix's innovative ARES™ X20+ automated fill-finish platform. It highlights how this technology can enhance manufacturing workflows for cell therapies, addressing significant challenges in scalability and consistency.

The Challenges of Cell Therapy Manufacturing

As cell therapy programs transition from smaller clinical studies to larger trials, the formulation and fill-finish processes can often become bottlenecks. Traditional methods, which rely heavily on manual handling or semi-automated systems, can lead to increased variability, heightened contamination risks, and additional handling requirements. Hence, there is a pressing need for scalable and reproducible procedures to ensure the integrity of the final product.

Key Findings from the White Paper

During their study, Cellipont evaluated the ARES™ X20+ platform across various scales of production. They discovered some compelling results, including:

• - Consistency Across Scales: The platform exhibited reliable performance even when process scale increased by roughly 17 times.
• - Formulation Accuracy: The final formulation volume achieved was impressively precise, with a 98.2% accuracy at smaller scales and exceeding 100% (103.6%) at larger scales, illustrating robustness across different batch sizes.
• - Cell Viability: One of the most important outcomes showcased stable cell viability pre and post-automation, affirming that the automated processes do not compromise cell integrity.

Darren Head, CEO of Cellipont Bioservices, emphasized the significance of these results. "Scaling cell therapy isn’t merely about generating more cells. It necessitates a comprehensive scaling of the entire manufacturing process to maintain consistency and readiness for clinical and commercial endeavors. A precise and consistent downstream formulation is critical to meeting these objectives."

Enhancements Driven by Evaluation Feedback

The evaluation served not only to validate the ARES™ X20+ platform's operational effectiveness but also to gather insights for further enhancements. Improvements focused on areas like:

• - Priming Efficiency
• - Single-Use Kit Capacity
• - Pressure Integrity Monitoring
• - Gravimetric Control
• - Pump Calibration and Product Recovery

Innovation Through Collaboration

Rachel Bahr, CEO of Xiogenix, remarked on the importance of collective innovation in this arena. "The best advancements happen through collaboration. Working closely with clients allows us to understand their unique challenges, as evidenced in our partnership with Cellipont. The ability to harness automation in scaling manufacturing presents an incredible opportunity to enhance both flexibility and consistency. Our ongoing commitment is to develop solutions that not only address immediate needs but also adapt and grow as client demands evolve."

Next Steps and Industry Engagement

To continue the dialogue around these findings and explore further insights into automated manufacturing, Cellipont Bioservices will participate in the upcoming CAR-TCR Summit, scheduled for September 15-17, 2026, in Boston. Key topics at the event will encompass the scalability of next-generation therapies and automated solutions.

For organizations interested in the detailed findings from the evaluation, the full white paper can be accessed through their dedicated channels.

About Cellipont Bioservices

Established as a leading CDMO, Cellipont Bioservices specializes in cell therapies, merging state-of-the-art technology with deep industry expertise. They offer a comprehensive suite of solutions that covers everything from process development to large-scale commercial production. Their outstanding facility and dedication to quality position them favorably for supporting biopharmaceutical companies as they strive to bring transformative therapies to market.

About Xiogenix

Xiogenix stands at the forefront of driving innovation in cell and gene therapy process automation. With an impressive portfolio that includes automated systems and single-use technologies, they can significantly improve the consistency and efficiency of manufacturing workflows. Their robust experience in regulated biologics has positioned them favorably to tackle complex challenges and enhance the availability of next-gen therapies.

To learn more about their respective offerings and innovations, explore the Cellipont and Xiogenix websites, and follow them on LinkedIn for the latest updates.